| scholarly article | Q13442814 |
| case report | Q2782326 |
| review article | Q7318358 |
| P50 | author | George K Dresser | Q116469852 |
| J. David Spence | Q43094507 | ||
| P2860 | cites work | SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid | Q57825144 |
| Carotid Ultrasound Phenotypes Are Biologically Distinct | Q58769489 | ||
| Statins and Cataracts: Reverse Causality? | Q58769544 | ||
| Effects of Intensive Medical Therapy on Microemboli and Cardiovascular Risk in Asymptomatic Carotid Stenosis | Q58770328 | ||
| Preventing Dementia by Treating Hypertension and Preventing Stroke | Q58771247 | ||
| Carotid Plaque Area and Intima-Media Thickness in Prediction of First-Ever Ischemic Stroke | Q63380980 | ||
| Drug interactions with grapefruit: whose responsibility is it to warn the public? | Q73293609 | ||
| Rosuvastatin increases alpha-1 microglobulin urinary excretion in patients with primary dyslipidemia | Q79272110 | ||
| High-dose atorvastatin after stroke or transient ischemic attack | Q80088259 | ||
| [Reduced synthesis of coenzyme Q10 may cause statin related myopathy] | Q82556884 | ||
| Effects of rosuvastatin and atorvastatin on renal function: meta-analysis | Q83552572 | ||
| Effect of coenzyme Q10 supplementation on statin-induced myalgias | Q84169460 | ||
| Coenzyme Q10 reverses mitochondrial dysfunction in atorvastatin-treated mice and increases exercise endurance | Q84268559 | ||
| Discontinuation of statin therapy due to muscular side effects: a survey in real life | Q84501478 | ||
| Balancing the cardiometabolic benefits and risks of statins | Q84774071 | ||
| Improvement of statin-associated myotoxicity by L-carnitine | Q45197186 | ||
| Ezetimibe and regression of carotid atherosclerosis: importance of measuring plaque burden | Q45719462 | ||
| Effects of simvastatin and carnitine versus simvastatin on lipoprotein(a) and apoprotein(a) in type 2 diabetes mellitus. | Q45925043 | ||
| Effect of L-carnitine on the size of low-density lipoprotein particles in type 2 diabetes mellitus patients treated with simvastatin. | Q45928533 | ||
| Long-term persistence with statin treatment in a not-for-profit health maintenance organization: a population-based retrospective cohort study in Israel | Q46183486 | ||
| Statin usage and all-cause and disease-specific mortality in a nationwide study | Q46421039 | ||
| Pharmacokinetics of rosuvastatin when coadministered with rifampicin in healthy males: a randomized, single-blind, placebo-controlled, crossover study. | Q46436953 | ||
| The safety of rosuvastatin as used in common clinical practice: a postmarketing analysis | Q46505797 | ||
| Metabolic myopathies discovered during investigations of statin myopathy. | Q46671140 | ||
| Lipid profile, statin use, and outcome after intravenous thrombolysis for acute ischaemic stroke. | Q46704364 | ||
| Lipid profiles and outcome in patients treated by intravenous thrombolysis for cerebral ischemia | Q47328159 | ||
| Statins do not cause intracerebral hemorrhage | Q48424813 | ||
| Statins are associated with a reduced risk of Alzheimer disease regardless of lipophilicity. The Rotterdam Study | Q48874488 | ||
| Impact of Dual Lipid-Lowering Strategy With Ezetimibe and Atorvastatin on Coronary Plaque Regression in Patients With Percutaneous Coronary Intervention: The Multicenter Randomized Controlled PRECISE-IVUS Trial | Q50439115 | ||
| Carotid plaque area: a tool for targeting and evaluating vascular preventive therapy. | Q50711584 | ||
| Myopathy during statin therapy in the daily practice of an outpatient cardiology clinic: prevalence, predictors and relation with vitamin D. | Q50937715 | ||
| Treating arteries instead of risk factors: a paradigm change in management of atherosclerosis. | Q51144514 | ||
| Statins and intracerebral hemorrhage: a retrospective cohort study. | Q53088871 | ||
| Adherence to statin treatment and health outcomes in an Italian cohort of newly treated patients: results from an administrative database analysis. | Q53675601 | ||
| Ethanol enhances the hemodynamic effects of felodipine. | Q54339719 | ||
| Coenzyme Q(10) and selenium in statin-associated myopathy treatment. | Q54446305 | ||
| Accumulating evidence for statins in primary prevention. | Q54535531 | ||
| Weighing the benefits of high-dose simvastatin against the risk of myopathy. | Q54581421 | ||
| Statin Use and the Risk of Incident Dementia | Q57392350 | ||
| Effects of atorvastatin and rosuvastatin on renal function: A meta-analysis | Q57618829 | ||
| Statin adverse effects : a review of the literature and evidence for a mitochondrial mechanism | Q24603957 | ||
| C-reactive protein concentration and the vascular benefits of statin therapy: an analysis of 20,536 patients in the Heart Protection Study | Q24617734 | ||
| Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis | Q24629045 | ||
| Effects of regular consumption of grapefruit juice on the pharmacokinetics of simvastatin | Q24679132 | ||
| Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management | Q28083004 | ||
| Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin | Q28142865 | ||
| Statins and stroke prevention | Q28166611 | ||
| A statin-dependent QTL for GATM expression is associated with statin-induced myopathy | Q28218899 | ||
| Squalene synthase inhibitors: An update on the search for new antihyperlipidemic and antiatherosclerotic agents | Q28246326 | ||
| Human skeletal muscle drug transporters determine local exposure and toxicity of statins | Q28265844 | ||
| Association between C reactive protein and coronary heart disease: mendelian randomisation analysis based on individual participant data | Q28742740 | ||
| Mitochondrial respiratory-chain diseases | Q29614474 | ||
| Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials | Q29617910 | ||
| SLCO1B1 variants and statin-induced myopathy--a genomewide study | Q29619028 | ||
| 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines | Q29620108 | ||
| Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials | Q29622947 | ||
| Statins, risk of dementia, and cognitive function: secondary analysis of the ginkgo evaluation of memory study | Q30417962 | ||
| Higher potency statins and the risk of new diabetes: multicentre, observational study of administrative databases. | Q33685412 | ||
| Effects of lovastatin on cognitive function and psychological well-being | Q33901538 | ||
| Effect of coenzyme q10 on myopathic symptoms in patients treated with statins | Q34004066 | ||
| Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis | Q34027392 | ||
| The association of statin use and statin type and cognitive performance: analysis of the reasons for geographic and racial differences in stroke (REGARDS) study | Q34078486 | ||
| Statin-associated myopathy | Q34187996 | ||
| Is statin-associated cognitive impairment clinically relevant? A narrative review and clinical recommendations | Q34219598 | ||
| Effect of a monoclonal antibody to PCSK9 on LDL cholesterol | Q34262650 | ||
| Targeting cellular energy production in neurological disorders | Q34266266 | ||
| The clinical pharmacogenomics implementation consortium: CPIC guideline for SLCO1B1 and simvastatin-induced myopathy. | Q34276618 | ||
| Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial | Q34293369 | ||
| Correlation between carotid intimal/medial thickness and atherosclerosis: a point of view from pathology | Q37579479 | ||
| Drug interactions with HMG-CoA reductase inhibitors (statins): the importance of CYP enzymes, transporters and pharmacogenetics. | Q37697094 | ||
| The myth of statin-induced hepatotoxicity | Q37743155 | ||
| Coenzyme q10 and statin-induced mitochondrial dysfunction. | Q37878308 | ||
| Statins and intracerebral hemorrhage: collaborative systematic review and meta-analysis. | Q37946869 | ||
| Novel LDL-oriented pharmacotherapeutical strategies. | Q37981532 | ||
| Monogenic mitochondrial disorders | Q37995644 | ||
| Carnitine and acylcarnitines: pharmacokinetic, pharmacological and clinical aspects | Q38026944 | ||
| Association of statin use with risk of dementia: a meta-analysis of prospective cohort studies | Q38086584 | ||
| Current Phase II proprotein convertase subtilisin/kexin 9 inhibitor therapies for dyslipidemia | Q38124404 | ||
| New therapies targeting apoB metabolism for high-risk patients with inherited dyslipidaemias: what can the clinician expect? | Q38126418 | ||
| Statins and cognition: a systematic review and meta-analysis of short- and long-term cognitive effects | Q38149604 | ||
| Carnitine therapy for the treatment of metabolic syndrome and cardiovascular disease: evidence and controversies | Q38212467 | ||
| Statin therapy and plasma coenzyme Q10 concentrations--A systematic review and meta-analysis of placebo-controlled trials | Q38550677 | ||
| Persistence and determinants of statin therapy among middle-aged patients free of cardiovascular disease | Q40390462 | ||
| Grapefruit juice-drug interactions. 1998. | Q42092985 | ||
| Liver tests are irrelevant when prescribing statins | Q42791971 | ||
| Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis | Q42791977 | ||
| Safety of Anacetrapib in Patients with or at High Risk for Coronary Heart Disease | Q42807626 | ||
| Oral acetyl-L-carnitine therapy and insulin resistance | Q43075364 | ||
| Impact of statin use and lipid profile on symptomatic intracerebral haemorrhage, outcome and mortality after intravenous thrombolysis in acute stroke | Q43483709 | ||
| Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia | Q44264759 | ||
| Effect of pravastatin on loss of renal function in people with moderate chronic renal insufficiency and cardiovascular disease | Q44449846 | ||
| Compliance and persistence with concomitant statin and oral antihyperglycemic therapy. | Q44508293 | ||
| Long term persistence with statin therapy -- experience in Australia 2006-2010. | Q44528592 | ||
| Previous statin use is not associated with an increased prevalence or degree of gradient-echo lesions in patients with acute ischemic stroke or transient ischemic attack | Q44532987 | ||
| Statin-associated rhabdomyolysis triggered by grapefruit consumption | Q44774923 | ||
| Carotid atherosclerosis is a stronger predictor of myocardial infarction in women than in men: a 6-year follow-up study of 6226 persons: the Tromsø Study | Q44902257 | ||
| Adherence to guideline-recommended therapy is associated with decreased major adverse cardiovascular events and major adverse limb events among patients with peripheral arterial disease. | Q34297015 | ||
| Safety of statins: focus on clinical pharmacokinetics and drug interactions | Q34327120 | ||
| Statin toxicity from macrolide antibiotic coprescription: a population-based cohort study | Q34351776 | ||
| Randomized trial of the effects of simvastatin on cognitive functioning in hypercholesterolemic adults | Q34374952 | ||
| Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial | Q34375398 | ||
| Statins and cognitive function: a systematic review | Q34386044 | ||
| Diagnosis, prevention, and management of statin adverse effects and intolerance: Canadian Working Group Consensus update | Q34387237 | ||
| Statin therapy for primary prevention of cardiovascular disease | Q34387879 | ||
| Effects of coenzyme Q10 on statin-induced myopathy: a meta-analysis of randomized controlled trials | Q34450426 | ||
| Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid | Q34467998 | ||
| Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes | Q34479098 | ||
| Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients--the PRIMO study | Q34490730 | ||
| Genetic risk factors associated with lipid-lowering drug-induced myopathies | Q34521375 | ||
| Interaction of citrus juices with felodipine and nifedipine | Q34567652 | ||
| Antifatigue effects of coenzyme Q10 during physical fatigue | Q34588341 | ||
| Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance | Q34592657 | ||
| The influence of SLCO1B1 (OATP1B1) gene polymorphisms on response to statin therapy. | Q34613443 | ||
| Discontinuation of statins in routine care settings: a cohort study | Q34644409 | ||
| Genetically elevated C-reactive protein and ischemic vascular disease | Q34868720 | ||
| Benefit-risk assessment of Rosuvastatin 10 to 40 milligrams | Q35209314 | ||
| Clinical pharmacokinetics of statins | Q35209512 | ||
| Mechanisms of statin-induced myalgia assessed by physiogenomic associations | Q35575560 | ||
| The effect of statins versus untreated dyslipidaemia on renal function in patients with coronary heart disease. A subgroup analysis of the Greek atorvastatin and coronary heart disease evaluation (GREACE) study. | Q35587723 | ||
| Evaluation of C-reactive protein prior to and on-treatment as a predictor of benefit from atorvastatin: observations from the Anglo-Scandinavian Cardiac Outcomes Trial | Q35756468 | ||
| Persistence and determinants of statin therapy among middle-aged patients for primary and secondary prevention | Q35826989 | ||
| Final conclusions and recommendations of the National Lipid Association Statin Safety Assessment Task Force. | Q36438054 | ||
| Statins for improving renal outcomes: a meta-analysis | Q36500899 | ||
| Approaches to the treatment of mitochondrial diseases | Q36524103 | ||
| A randomized trial of coenzyme Q10 in patients with statin myopathy: rationale and study design | Q36899354 | ||
| Simvastatin impairs exercise training adaptations | Q37100826 | ||
| Effects of simvastatin 40 mg daily on muscle and liver adverse effects in a 5-year randomized placebo-controlled trial in 20,536 high-risk people | Q37177038 | ||
| Molecular basis of statin-associated myopathy | Q37202013 | ||
| Statin myopathy as a metabolic muscle disease | Q37230388 | ||
| Genetic predisposition to statin myopathy | Q37306393 | ||
| P275 | copyright license | Creative Commons Attribution-NonCommercial | Q6936496 |
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | cardiovascular disease | Q389735 |
| muscular disease | Q692536 | ||
| statin | Q954845 | ||
| insulin resistance | Q1053470 | ||
| lipid | Q11367 | ||
| diabetes | Q12206 | ||
| statin therapy | Q62562875 | ||
| dyslipidemia | Q66291209 | ||
| P5008 | on focus list of Wikimedia project | ScienceSource | Q55439927 |
| P304 | page(s) | e002497 | |
| P577 | publication date | 2016-01-27 | |
| P1433 | published in | Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease | Q19880670 |
| P1476 | title | Overcoming Challenges With Statin Therapy | |
| P478 | volume | 5 |
| Q88766431 | A comprehensive review and meta-analysis of risk factors for statin-induced myopathy |
| Q41678728 | Appropriate management of asymptomatic carotid stenosis |
| Q60301234 | Association of medication adherence and depression with the control of low-density lipoprotein cholesterol and blood pressure in patients at high cardiovascular risk |
| Q58769018 | Controlling resistant hypertension |
| Q55292729 | Free triiodothyronine level correlates with statin responsiveness in acute myocardial infarction. |
| Q26740304 | Recent advances in pathogenesis, assessment, and treatment of atherosclerosis |
| Q99630523 | Recent advances in preventing recurrent stroke |
| Q33873364 | Recent advances in preventing stroke recurrence |
| Q64062792 | Statins and Inflammation: New Therapeutic Opportunities in Psychiatry |
| Q90224258 | The Signaling Pathways Involved in the Antiatherosclerotic Effects Produced by Chinese Herbal Medicines |
| Q47255965 | Treatment patterns and low-density lipoprotein cholesterol (LDL-C) goal attainment among patients receiving high- or moderate-intensity statins |
Search more.